Enhanced Astrocytic Nitric Oxide Production and Neuronal Modifications in the Neocortex of a NOS2 Mutant Mouse

Yossi Buskila1, Yasmin Abu-Ghanem1, Yifat Levi1, Arie Moran1, Ettie Grauer2, Yael Amitai1*

1 Department of Physiology, Faculty of Health Sciences, Ben-Gurion University, Beer-Sheva, Israel, 2 Department of Pharmacology, Israel Institute for Biological Research, Ness-Ziona, Israel

Background. It has been well accepted that glial cells in the central nervous system (CNS) produce nitric oxide (NO) through the induction of a nitric oxide synthase isofrom (NOS2) only in response to various insults. Recently we described rapid astroglial, NOS2-dependent, NO production in the neocortex of healthy mice on a time scale relevant to neuronal activity. To explore a possible role for astroglial NOS2 in normal brain function we investigated a NOS2 knockout mouse (B6;129P2-Nos2tm1Lau/J, Jackson Laboratory). Previous studies of this mouse strain revealed mainly altered immune responses, but no compensatory pathways and no CNS abnormalities have been reported. Methodology/Principal Findings. To our surprise, using NO imaging in brain slices in combination with biochemical methods we uncovered robust NO production by neocortical astrocytes of the NOS2 mutant. These findings indicate the existence of an alternative pathway that increases basal NOS activity. In addition, the astroglial mutation instigated modifications of neuronal attributes, shown by changes in the membrane properties of pyramidal neurons, and revealed in distinct behavioral abnormalities characterized by an increase in stress-related parameters. Conclusions/Significance. The results strongly indicate the involvement of astrocytic-derived NO in modifying the activity of neuronal networks. In addition, the findings corroborate data linking NO signaling with stress-related behavior, and highlight the potential use of this genetic model for studies of stress-susceptibility. Lastly, our results beg re-examination of previous studies that used this mouse strain to examine the pathophysiology of brain insults, assuming lack of astrocytic nitrosative reaction.

INTRODUCTION

Nitric oxide (NO) is produced in the brain by neurons, astroglia and endothelial cells, and is known to participate in diverse signaling pathways. Three different isoforms of the enzyme nitric oxide synthase (NOS) synthesize NO from L-arginine, and their activity depends on the setting and the cell type involved. For example, neurons expressing the neuronal NOS isoform (NOS1) are capable of rapid release of small amounts of NO serving as neurotransmitter [1,2]. On the other hand, astroglial NO production has been demonstrated mainly as a reaction to various detrimental stimuli such as ischemia or inflammation, through the activity of a stress-induced NOS isoform (NOS2) that can produce large amounts of NO, but on a much slower time scale [e.g. 3–7]. Using NO imaging in brain slices we recently demonstrated NOS2-dependent astroglial NO production, which occurred on a fast time scale (seconds) and did not involve de-novo protein synthesis [8]. These data raised, for the first time, the possibility of the involvement of astroglial-derived NO in physiological brain activity.

To test for a possible role for astroglial, NOS2-dependent NO in normal brain function, we evaluated a NOS2 knockout mouse (B6;129P2-Nos2tm1Lau/J, Jackson Laboratory, http://jaxmice.jax.org/strain/002596rf.html). In this mouse strain, the fragment containing the calmodulin-binding domain of NOS2 was replaced by the neomycin resistance gene [9]. Homozygous NOS2 mutant mice are fertile, and display no developmental defects or abnormalities of blood composition. Over the past ten years, more than 100 published studies have used these NOS2 mutants to explore the role of the enzyme in various organ systems. It has been reported that these mice have no serum NO response under conditions of immune challenge, their macrophages do not produce NO in culture, and they exhibit altered responses to various systemic infections, though they are not considered immune-compromised [9–11]. No compensatory pathway has been identified in this mouse strain until now.

Only a few studies have explored some aspects of brain function in these mutants. Almost all these studies used the mutant in various models for brain pathologies such as ischemia, Alzheimer’s or Parkinson’s disease, focusing on the role of NOS2 induction in the long-term outcome of the insult. The mutants were compared to control mice, assuming they lack astroglial NO production [e.g. 12–16]. The behavior of these mutants received little attention, probably due to the current conviction that maintains that NOS2 does not participate in normal brain activity.

In the current study we demonstrate robust NO production by astroglia in the mutants’ neocortex, suggestive of a constitutive alternative pathway. The data also imply that the mutation lead to neuronal modifications, and a distinct behavioral phenotype. Some of these data have been published in an abstract format (Buskila et al., SIN abst., Atlanta 2006).

Citation: Buskila Y, Abu-Ghanem Y, Levi Y, Moran A, Grauer E, et al (2007) Enhanced Astrocytic Nitric Oxide Production and Neuronal Modifications in the Neocortex of a NOS2 Mutant Mouse. PLoS ONE 2(9): e843. doi:10.1371/journal.pone.0000843

Academic Editor: Mark Cookson, National Institutes of Health, United States of America

Received December 18, 2006; Accepted August 13, 2007; Published September 5, 2007

Copyright: © 2007 Buskila et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The study was supported by a grant from the Israel Science Foundation to Yael Amitai.

Competing Interests: The authors have declared that no competing interests exist.

* To whom correspondence should be addressed. E-mail: yaela@bgu.ac.il
RESULTS

Mutants’ astrocytes exhibit NOS activity

We first examined whether the NOS2 mutation eliminated astroglial NO production as expected. We incubated cortical slices from mutant and control mice in the NO indicator diaminofluorescein–2 diacetate (DAF-2DA) to image NO-producing cells. The fluorescence intensity (FI) of this indicator is expected to roughly correlate with the concentration of NO and peroxinitrite and hence, with NOS activity [17,18]. The staining pattern observed under the fluorescent light in slices from control mice was identical to previously described DAF-2DA fluorescence patterns observed under the fluorescent light in slices from control CD1 mice [8]. Briefly, punctate, putative neuronal staining appeared almost immediately and decayed within 60 to 90 seconds. Putative astroglia staining appeared later, at variable times from the start of illumination (usually >120 sec), displaying bright diffuse staining (Fig 1A). In contrast, slices from mutant mice exhibited widespread cellular fluorescence immediately after opening the fluorescence shutter. The fluorescence pattern was mixed, and both punctate and diffuse staining could be observed. Longer illumination periods led to a rapid increase in the number of diffusely fluorescent cells resulting in considerable overlap and making it impossible to differentiate single cell somata (Fig 1A). The non-selective NOS inhibitor L-NAME (1 mM) abolished all fluorescent responses in slices from both mutant (n = 4 slices, 2 animals) and control (n = 4 slices, 2 animals) mice, corroborating it was due to NOS activity.

Fig 1B displays FI analysis of identified cells over time, demonstrating faster and more intense fluorescent response in slices from mutant compared with control mice. Since FI of single diffusely-stained cells reached saturation levels in both control and mutant mice, it can be deduced that in mutant slices, the rapid increase in FI was caused mainly by a higher number of cells participating rapidly and simultaneously in NO production.

Previous data suggested that the reason for the delayed astroglial DAF-2DA fluorescence in CD1 mice is an unidentified activation step which was triggered by phototoxic neuronal death [8]. In agreement with this idea, diffuse astroglial staining was rarely observed in DAF-2DA loaded slices from control mice when imaged with a confocal microscope. In contrast, cells exhibiting diffuse fluorescence pattern were readily noticeable and widespread under the confocal microscope in slices from mutant mice (n = 8 slices, 3 animals, Fig 2A). Thus, the diffuse fluorescent response in the mutant did not require any preceding event, but rather the NOS isoform in these cells was probably constitutively active. In addition, diffuse DAF-2DA fluorescence in mutant slices was almost fully co-localized with the specific astrocytic marker SR101 [19] (Fig 2B,C), establishing that the pattern of DAF-2DA staining has not been altered in the mutant, and the cells exhibiting diffuse fluorescence are astrocytes.

Whole-cell recordings from diffusely stained cells in slices from control mice disclosed low membrane resistance (Ri 30.6 ± 23.2 MΩ, n = 6) and passive membrane properties characteristic of astroglia. We also recorded from diffusely-stained cells in mutant slices and examined their electrophysiological properties: all the recorded cells (n = 6) revealed low input resistance (average 34.1 ± 19.4 MΩ), a linear I-V relationship and lack of action potential firing upon depolarization (Fig 3). There were no...
significant differences between astrocytes from the mutant and control mice in their electrophysiological properties, and these were similar to previously published data on astrocytes in CD1 mice [8]. Taken together, these findings indicate that astrocytes in the mutant mice express an active NOS isoform.

### NOS activity in mutant astroglia is ca\(^{2+}\)-dependent

To identify the isoform responsible for the augmented fluorescent response in mutant mice we used specific NOS inhibitors. An inhibitor of constitutive NOS isoforms, L-NNA (1 \(\mu\)M), abolished all fluorescent reaction in slices from both mutant (\(n = 5\) slices, 2 animals) and control mice (\(n = 5\) slices, 2 animals). 1400W is considered today the most selective NOS2 inhibitor, as it inhibits NOS2 with 5000- and 200-folds greater potency than NOS3 and NOS1, respectively [20]. Incubating brain slices for 30 minutes in a ringer solution containing 1400W (3 \(\mu\)M) had no effect on the punctate, neuronal fluorescence in slices from either mutant or control mice (Fig. 4, 30 sec). On the other hand, 1400W abolished the astrocytic diffuse fluorescence in all slices from control (\(n = 6\) slices, 2 animals), but not in slices from mutant mice, where multiple diffusely-stained astrocytes were clearly visible (Fig 4, 180sec, \(n = 7\) slices, 3 animals). These findings are consistent with the premise that the NOS2 protein in astroglia of mutant mice has been modified, and its pharmacological sensitivity to the drug has been altered.

NOS2 activity is considered independent of intracellular Ca\(^{2+}\) concentration. Knowing that the mutation was directed at the calmodulin-binding domain of the protein, we hypothesized that the compensatory NOS isoform is Ca\(^{2+}\)-dependent, similar to the constitutive isoforms. Indeed, cultured astrocytes from mutant mice exhibited significantly lower NOS activity compared with cultured astrocytes from control mice when calcium was omitted from the medium (27.8±28.03 and 106.6±55.8 nmole nitrite respectively, p=0.01).

Since intracellular Ca\(^{2+}\) elevation in astrocytes occurs, for the most part, through mobilization from internal stores [21–24] we depleted the internal Ca\(^{2+}\) stores by incubating the slices for 45 minutes in thapsigargin (5 \(\mu\)M), an inhibitor of the endoplasmic reticulum Ca\(^{2+}\)-ATPase. The neuronal, punctuate DAF-2DA fluorescence in either mutant or control slices was not affected by the thapsigargin pre-incubation (Fig 3A), in agreement with data showing that neuronal NO production depends mainly on Ca\(^{2+}\) entering through NMDA channels [25,26]. The diffuse astroglial fluorescence in control slices was also unaffected by thapsigargin, and multiple cells could be distinguished in each visual field at time points later than 120 seconds following the start of illumination. In contrast, thapsigargin almost completely blocked the astrocytic fluorescence in slices from mutant mice (Fig 5B), a result which is consistent with a role for intracellular calcium stores in mediating NOS activity in these cells.

### Basal NOS activity in the mutant is increased

We next used western blot analysis to examine whether the expression of either of the constitutive NOS isoforms, NOS1 or NOS3, was increased in the mutant neocortex. To test for expression of the mutated protein we used antibodies specific against the NOS2 protein N-terminus. We found tight conservation of the total and relative expression of all three NOS isoforms in the NOS2 mutant, with protein ratios between mutants and control neocortex measuring 88±16% for NOS1, 106±17% for NOS2, and 103±17% for NOS3 (p>0.05, \(n = 6\) animals of each strain, Fig 6A). Immunohistochemistry against NOS1 or NOS3 and glial fibrillary acidic protein, a classic marker for astroglia, did not reveal any co-localization (not shown). Thus, no evidence was found for a compensatory increase in expression of the NOS1 or NOS3 isoforms in astroglia of the mutant mouse. Moreover, the total protein level of NOS isoforms is unchanged, indicating that the increase in basal NOS activity seen by NO fluorescent imaging in the mutants cannot be explained by a change in isoform expression.

The use of DAF-2DA fluorescence for establishing NO concentrations is complicated by its reactivity to peroxynitrite [18] and its dependence on light intensity [27]. Therefore, to compare the basal NOS activity between the neocortex of mutant and control
mice, we used an independent method which measures directly the conversion of radiolabeled L-arginine to L-citrulline [28]. Consistent with the imaging data, we found a 30% increase in the total NOS activity in brains of mutant mice, compared with controls (avg. activity 506.8 ± 25.9 and 391.2 ± 36.8 pmole/30 min/mg protein respectively; p = 0.01, Fig 6B). The Ca\(^{2+}\)-independent NOS fraction was measured by omitting Ca\(^{2+}\) from the reaction buffer. This fraction did not differ significantly between the two mice strains, and in both cases it comprised less than 10% of the total NOS activity. Taken together, these data suggest that the NOS2 mutation led to an increase in the basal levels of Ca\(^{2+}\)-dependent NOS activity.

**Mutant mice exhibit a behavioral phenotype**

We suspected that the alteration in NOS activity in the mutants' astrocytes may have affected neighboring neurons. Studies using immunohistochemistry reveal that in the neocortex, only a small subpopulation of GABAergic interneurons express the isoform NOS1 [29,30]. In agreement with these data, pyramidal neurons recorded in DAF-2DA-loaded slices from either mutant or control did not exhibit any fluorescence (Fig. 7). Nevertheless, pyramidal neurons from mutant mice exhibited significantly higher input resistance and longer membrane time constant than neurons from control mice, and were similar in all other electrical parameters examined (Table 1).

Assuming that these single neuron modifications express a developmental adjustment, we next examined whether more aspects of neuronal activity have been modified leading to detectable behavioral changes. NOS2 mutant mice had normal reflexes and no apparent motor deficit. Testing their basic exploratory behavior, we found no differences between control and mutant mice in their general activity, both in the Open-Field and the Hole-Board tests (Fig 8A,B). In contrast, clear differences between the groups were observed in stress-related parameters. For example, grooming during Open Field and Hole Board tests was almost completely suppressed in mutant compared to control mice (Fig 8B, p = 0.001), while in the safety of their home cages, mutant mice displayed normal grooming behavior. With repeated Hole Board testing grooming increased in both groups, but control mice increased their grooming periods more than mutant mice such that the difference between the groups became even more pronounced (Fig 8B, Open Field, p<0.001; Hole Board, p<0.001). Furthermore, mutant mice displayed increased freezing when initially placed in the center of a square-shaped Open Field (p = 0.002), reared less (p = 0.008), and ventured less into the center of the field (p = 0.039) than control mice (Fig 8A).

The mice were also tested in the Elevated Plus maze, a standard test for fear and anxiety. Mutant mice fully avoided the open arms (p = 0.003), remained longer in the closed arms (p = 0.004), and exhibited significantly less head-dipping and stretch/attend postures, behavior which is commonly interpreted as "risk assessment" (p = 0.001). To examine whether increased NOS activity could have contributed to the development of this heightened anxiety, the performance of the mutant mice on the Elevated Plus maze was examined 10 hours following systemic administration of L-NAME (50 μM/kg). At this time point, the effect of L-NAME on arterial blood pressure is expected to be over, while brain NOS activity is still reduced by about 30% [31]. When compared to saline-injected mutant mice, the L-NAME treated mice spent significantly more time in the open arms (p = 0.02), less time in the closed arms (p = 0.008), and increased the frequency of their risk assessment behavior (p = 0.02). Overall, the performance of L-NAME treated mutant mice on the Elevated Plus maze was comparable to that of control mice (Fig 9). Together these data uncover a distinct behavioral phenotype according to which the NOS2 mutant mice are more susceptible to stress, a trait likely to be related to an increased basal NOS activity in their CNS.

**DISCUSSION**

Genetically engineered mice with interruptions of the specific NOS genes were developed to help in elucidating the role of NO and the NOS isoforms [10,11]. However, it has been obvious for some time now that altered genes might affect many developmental processes, and compensatory mechanisms may be activated in knockouts. We demonstrate here intense NO production by astroglia in brains of homozygous NOS2 mutant mice. The data presented is strongly indicative of a constitutive, alternative pathway, which resulted in increased levels of basal NOS activity. In addition, we found that the astrocytic mutation instigated neuronal modifications: 1) neocortical pyramidal neurons exhibit mild but significant changes in their membrane properties, and 2) the mutant mice display a distinct behavioral phenotype.
The biochemical modifications
While the neuronal DAF-2DA fluorescent response in slices from mutant and control mice was identical on all parameters of analysis, several findings clearly discerned the astrocytic response in mutant from control slices: 1) the fluorescence developed faster and reached higher intensity in mutant slices due to a large number of fast-reacting cells, 2) the fluorescence in mutant astroglia was insensitive to the NOS2 inhibitor 1400W, while this compound completely abolished it in control slices, and 3) astroglial fluorescence in the mutant, but not in the control, depended on release of Ca\(^{2+}\) from internal stores. Although there were no changes in the expression levels of any of the three NOS isoforms, NOS activity in neocortex of mutant mice was considerably increased compared with control neocortex.

The exact nature of the biochemical modifications has not been clarified here. The imaging experiments indicate that the compensatory process occurs mainly in astrocytes. The likely possibility is that the mutated protein is now constitutively expressed and uses an alternative pathway. Another possibility for the underlying mechanism is that higher activity of the other constitutive NOS isoforms is compensating for the reduced activity of the mutated protein. However, we failed to find evidence for the expression of the NOS1 or NOS3 isoforms in mutant astroglia to support this possibility.

Whatever is the nature of the biochemical modifications, their existence needs to be taken into account when evaluating brain function in these mutants. It has been well accepted that under pathological conditions, NOS2 expression in astrocytes increases

Table 1. Comparison of electrophysiological properties between pyramidal neurons of mutant and control neocortex.

|                | Vm (mV)   | Ri (MΩ)   | rm (ms)   | Spike Amp (mV) | Spike width, 1/2 amp (ms) |
|----------------|-----------|-----------|-----------|----------------|-------------------------|
| Mutant (n = 12)| -71.0±4.3 | 311.2±91.7 | 23.3±10.2 | 72.1±9.1       | 1.7±0.5                 |
| Control (n = 13)| -70.1±4.08 | 237.7±90.8 | 15.7±4.9  | 76.1±8.3       | 1.4±0.4                 |

Pyramidal neurons were recorded in layer 5 of the primary somatosensory cortex.
Data is expressed as mean±SD. *p = 0.028; **p = 0.013, student t-test.

doi:10.1371/journal.pone.0000843.t001
dramatically over a period of hours and days. Hence, several groups used this same NOS2 mutant strain to examine the role of NO in the long-term outcome of brain insults, assuming lack of astrocytic NO production under these conditions. Most notably, these mice were found to be more resistant to MPTP neurotoxicity, a model for Parkinson’s disease \cite{12,13,32}. On the other hand, the use of these mutants in different models for Alzheimer’s disease has yielded disparate views about the role of NO in this neurodegenerative disease \cite{14,33}. The conclusions of these studies and specifically their mechanistic explanations need to be re-evaluated in light of these results.

The behavioral phenotype
Both NOS1 and NOS3 knockout mice exhibit distinct behavioral phenotypes, which are unrelated to other systemic alterations such as changes in their blood pressure \cite{34,35}. Although used by many researchers for over 10 years, no description of behavioral alterations in NOS2 mutants has been published. Our findings delineate a distinct behavioral phenotype in a NOS2 mutant mouse. Interestingly, an earlier study reported changes in the sleep pattern of these mice \cite{36}, supporting the finding of CNS modifications. The association between NO and stress-related behavior has been well documented, and pharmacological studies suggest that NO plays an important role in mediating defensive responses \cite{reviewed in 37}. For example, NO signaling has been demonstrated to contribute to fear conditioning in the lateral amygdala \cite{38}, CNS injections of NOS inhibitors induce anxiolytic effects in the Elevated Plus maze \cite{39,40}, whereas flight reactions have been seen after administration of NO donors \cite{41,42}. Thus, the enhanced stress related behaviors of the NOS2 mutant is consistent with these data and is in accord with enhanced NOS activity. The unique finding in our study is the detection of astrocytes as the likely cellular source for the increased NO in mutant mice, and not neurons as typically assumed.

The cellular source of NO as neuromodulator
The role of NO as a retrograde messenger mediating presynaptic activity-dependent changes has been investigated intensely. While the involvement of the NO-cGMP pathway is relatively established \cite[e.g. 1,2,43,44], its cellular source remains doubtful. Clearly, identifying the cells producing NO to participate in modulating physiological neuronal activity is of great importance for understanding the mechanisms that control its production and its biological role.

In the neocortex, NOS1 is expressed only by a somatostatin-expressing subtype of GABAergic interneurons \cite{29,30}. It was demonstrated also in spines of hippocampal pyramidal neurons
[45,46], but not in the neocortex. NOS3 is found mostly in the vascular endothelium, and its expression by neurons has been controversial [47,48]. Our own imaging data are in agreement with this neuronal NOS distribution: while pyramidal neurons in the hippocampus display DAF-2DA fluorescence [personal observation,49], neocortical pyramidal neurons do not. It has been also proposed recently that NO released from endothelial cells participates in modulating nerve cells [50]. The glial option has been largely ignored as the data existing emphasized the expression of astroglial NOS2 only through gene induction following various damage-causing stimuli. Yet, a recent study using spinal-cord slice preparation demonstrated that synaptic potentiation of the postsynaptic afferents was mediated by NO released from glial cells, via mGluR1 activation [51]. The NOS2 mutant provides additional evidence, though indirect, for the involvement of astroglial-derived NO in modifying the activity of large neuronal networks as expressed by the intricate stress related behavior.

In recent years it has become increasingly apparent that astrocytes maintain dynamic reciprocal communication with neurons, and may contribute to the regulation of neuronal activity. As part of this concept, the synaptic structure is viewed as the ‘tri-paritite synapse’, in which astrocytes play an active role in modulating synaptic transmission [52–54]. We speculate that the biochemical compensatory changes in the NOS2 mutant brain described here reflect an essential role for astrocytic NO production, and that astrocytic-produced NO participates in neuronal modulation in the normal brain.

MATERIALS AND METHODS

Animals

Homozygous mice for the Nos2<sup>grep1Lau</sup> targeted mutation (Nos2-deficient mice, B6;129P2-Nos2<sup>grep1Lau</sup>/J) and their wild-type control (B6;129PF2/J) were obtained from Jackson Laboratories (Bar Harbor, ME). Animals were healthy, and handled routinely under standard conditions of temperature, humidity and a 12 h light/dark cycle, with free access to food and water. All experiments were approved by the Ben-Gurion university committee for the ethical care and use of animals in experiments.

Imaging and recording in slices

Mice (14–21 days old) were deeply anesthetized with pentobarbital, decapitated, and their brains quickly removed into cold (5°C) physiological solution. Selective astrocytic labeling with SR101 (50 μM in ACSF, Sigma) was done by pressure injection into the neocortex using a picospritzer (General Valve corp.) about 2 minutes prior to decapitation. Neocortical slices (300–400 μm thick) were cut with a vibratome (Campden Instruments, London) and kept in a holding chamber at 36°C for at least 1 hour before any treatment [55], continuously bubbled by 95%O<sub>2</sub>-5%CO<sub>2</sub>. The bathing and superfusing solution contained (in mM): 124 NaCl, 3.5 KCl, 1.25 NaHPO<sub>4</sub>, 2 CaCl<sub>2</sub>, 26 NaHCO<sub>3</sub>, 10 dextrose, and was saturated with 95%O<sub>2</sub>-5%CO<sub>2</sub> (pH 7.4). For NO-imaging experiments, the slices were incubated in Diamino-fluorescein-2 Diacetate (DAF-2DA, 2 μM, Calbiochem, La Jolla, CA) for 10 minutes, and then transferred to a slice chamber mounted on an upright fluorescence microscope equipped with IR/DIC optics (Nikon physiotation EC-600), where they were kept at 30–32°C and constantly perfused. Illumination was done with a fluorescent light source (100W mercury lamp), via a Nikon filter (excitation wavelength 450–490 nm, emission wavelength 520 nm), using 60× water immersion objective. Imaging was done using a black and white CCD camera with integrating frame grabber control unit (CCD-300FG, Dage-MTI, USA), integrating 16 frames for each image. Confocal imaging was done from live slices using a C1si spectral confocal system. The perfusion chamber was mounted on a Nikon FN1 upright microscope equipped with a 1.0 NA water-dipping objective. DAF-2DA images were acquired using the 488 nm line of a 65 mW Argon laser, and SR101 was imaged with a 543 nm HeNe laser.

Fluorescence intensity (FI) was measured off-line using J-image software (Wayne Rasband, NIH). Two types of analysis were carried out. We measured FI of single cells in focus by defining the area of analysis when cells’ somata were clearly separable. Otherwise, we measured the FI of the whole visual field. The background was subtracted in both cases.

Whole-cell recordings were performed from neurons and glia with patch pipettes (3–5 MΩ), containing (in mM): 125 K-glucuronate, 2 MgCl<sub>2</sub>; 10 HEPES; 10 EGTA; 5 NaCl; 2 Na<sub>2</sub>ATP, pH 7.2, 280 mOsm. Voltages were recorded using patch-clamp amplifier (AxoPatch 2B, Axon Instruments), digitally sampled at 10 kHz and analyzed off-line using LabView-based software. Series resistance was typically <15 MΩ.

The following drugs were added to the incubating solution at various time intervals before imaging, and the same concentration was maintained in the superfusing solution during imaging, unless noted otherwise: N<sub>e</sub>-Nitro-L-arginine (L-NAME); N-Nitro-L-arginine methyl ester (L-NAME); Thapsigargin, all purchased from Sigma-Aldrich, Israel, and N-[3 (aminomethyl) phenyl]ethyl]anilinomida dihydrochloride (1400W) was purchased from Tocris (Bristol, UK).

Western Blot Analysis

The neocortex was dissected immediately following decapitation, homogenized in ice-cold lysis buffer, and centrifuged at 14,000 rpm for 15 min. The supernatant was collected and assayed for total protein concentration using the Bradford method [56]. Samples containing 50 μg proteins were loaded and the protein size was separated in 7.5% SDS polyacrylamide gel electrophoresis (150 V) along with a set of molecular-weight markers (Bio-Rad, UK). Blots were electrotransferred onto nitrocellulose membrane, blocked with blocking buffer, and then incubated overnight with specific primary polyclonal antibodies against Nos1 (1:200–1:500), Nos2 (1:200–1:1000) and Nos3 (1:200), all of them purchased from Santa Cruz Biotechnology, CA. Positive controls from macrophages were used for Nos2. Blots were exposed to horseradish peroxidase-conjugated anti-rabbit IgG secondary antibody (1:7,500, Santa Cruz Biotechnology), and immunoreactivity was visualized using Chemilumager technology, following manufacturer’s instructions (Alpha Innotech Corporation, San Leandro, CA).

NOS activity assays

NOS catalytic activity was assayed by measuring both the Ca<sup>2+</sup>-dependent and the Ca<sup>2+</sup>-independent conversion of [3H]arginine to [3H]citrulline as described by Przedborski et al. [28], using Nos activity assay kit (Cayman chemicals, Ann Arbor, MI). In brief, brains of 21 days old mice were quickly removed and the neocortex was homogenized in 1 ml buffer containing 25 mM Tris-HCl (pH 7.4), 1 mM EDTA and 1 mM EGTA. Samples were incubated at room temperature for 30 min in the presence of [3H]-arginine (1 μCi/μl; Amersham, UK) and cofactors. The reaction was terminated by the addition of stop buffer containing 50 mM HEPES (pH 5.5) and 5 mM EDTA. To determine the relative fraction of calcium-independent NOS activity, calcium was omitted from the reaction mixture in some samples and EGTA (1 mM) was added. [3H]-citrulline was quantified by liquid
scintillation counting of the eluate, and the counts per minute for all samples were averaged and corrected with respect to the background radioactivity. NOS activity was expressed as pmol [14C] L-citrulline/30 min/mg protein.

To compare NOS activity between cultured astrocytes from mutant and control mice, nitrite concentrations were determined using an assay kit based on the reaction of nitrite with 2,3-diaminomorpholine to form the fluorescent product, 1-[H]-naphthothiazole (Calbiochem, Cat. No. 482655), following standard instructions. The reading was performed with wavelengths of 365 nm excitation, and 450 nm emission.

Behavioral testing

Control and mutant adult male mice were transferred to the lab prior to testing, and remained there throughout the testing period. The animals were neither handled nor habituated to the behavioral apparatus before the initial test session. Tests were carried out during the light period (12:00–16:00). Mouse behavior was recorded from a centrally placed video camera located 0.5 m away from the apparatus under dim light. A hole-board was used to examine explorative behavior. Each animal was placed in the center of the board and its behavior videotaped for 5 minutes, and the test was repeated for three successive days. Head dipping and grooming episodes, as well as distant travel on the board were recorded off the videotapes. For the Open-Field test, each mouse was placed in the center of the field and its latency to escape to any corner was recorded. The behavior was videotaped for 10 minutes, and the following parameters were recorded: the field was divided into 25 squares (20 cm × 20 cm each) and the total (center and peripheral) squares crossed, the distance traveled, the number of entries into the center of the field, and the number of rearing and grooming episodes. The test was repeated over a total of three consecutive days. An Elevated Plus maze with two open and two closed arms (each 30 cm long × 5 cm wide) was used for a single 10-minutes exposure. The time spent in the open arms and duration of grooming were recorded off the videotapes as well as the number of partial (2 legs) and full (4 legs) entries into the open arms, the number of stretch/attend postures, and the head dipping over the side of the open arms (the combined last two parameters were interpreted as “risk assessment” behavior). Two-way analysis of variance (ANOVA) with repeated measure was used to examine group differences over days (when tested), with a significance level of 0.05.

ACKNOWLEDGMENTS

Author Contributions

Conceived and designed the experiments: YA YB AM EG. Performed the experiments: VB YA VL. Analyzed the data: YA YB YA. Contributed reagents/materials/analysis tools: AM. Wrote the paper: YA YB AM EG.

REFERENCES

1. Pratt H, Philippu A (2001) Nitric oxide as modulator of neuronal function. Prog Neurobiol 1: 51–69.
2. Boehning D, Snyder SH (2003) Novel neural modulators. Annu Rev Neurosci 26: 106–131.
3. Licinio J, Prolo P, McCann SM, Wong ML (1999) Brain iNOS: current understanding and clinical implications. Mol Med Today 5: 225–232.
4. Lopez-Figueroa MO, Day HEW, Lee S, Rivier C, Akil H, et al. (2000) Temporal and anatomical distribution of nitric oxide synthase mRNA expression and nitric oxide production during central nervous system inflammation. Brain Res 852: 239–246.
5. Moro MA, Gardenas A, Hurtado O, Lema JC, Lizaroaín I (2004) Role of nitric oxide after brain ischaemia. Cell Calcium 36: 275–285.
6. Murphy S (2000) Production of nitric oxide by glial cells. J Physiol 529: 1–14.
7. Ollivenza R, Moro MA, Lizaroaín I, Lorenzo P, Fernandez AP, et al. (2000) Chronic stress induces the expression of inducible nitric oxide synthase in rat brain cortex. J Neurochem 74: 785–791.
8. Buskila Y, Farkash S, Hershfinkel M, Amitai Y (2005) Rapid and reactive nitric oxide production by astrocytes in mouse neocortical slices. J Physiol 562: 169–76.
9. Lanbuch VE, Shesely EG, Smithies O, Sherman PA (1993) Mice lacking inducible nitric oxide synthase are not resistant to lipopolysaccharide-induced death. Proc Natl Acad Sci USA 92: 10636–10642.
10. Mashimo H, Goyal RK (1999) Lessons from genetically engineered animal models. IV. Nitric oxide synthase gene knockout mice. Am J Physiol 277: G745–50.
11. Mungre IN, Brett DS, Stewart DJ, Husain M (2003) From molecules to understanding and clinical implications. Mol Med Today 5: 225–232.
12. Liberatore JT, Jackson-Lewis V, Crunelli V (2001) Spontaneous astrocytic Ca2+ transients in astrocytes in situ. J Neurosci 21: 9430–9441.
13. Parri HR, Gould TM, Crunelli V (2001) Spontaneous astrocytic Ca2+ oscillations in situ drive NMDAR-mediated neuronal excitation. Nat Neurosci 4: 803–12.
14. Aguado F, Espinosa-Pallara JF, Cormano MA, Soriano E (2002) Neuronal activity regulates correlated network properties of spontaneous calcium transients in astrocytes in situ. J Neurosci 22: 9430–9441.
15. Perea G, Araque A (2003) Glial calcium signaling and neuron-glia communication. Cell Calcium 35: 375–82.
16. Volterra A, Meldolesi J (2005) Astrocytes, from brain glue to communication elements: the revolution continues. Nat Rev Neurosci. 6: 626–40.
17. Garthwaite J, Boulton CL (1995) Nitric oxide signaling in the central nervous system. Annu Rev Physiol 57: 683–706.
18. Christopherson KS, Hillier BJ, Lim WA, Brett DS (1999) PSD-95 associates a ternary complex with the N-methyl-D-aspartic acid receptor and a bivalent neuronal NO synthase PDZ domain. J Biol Chem 274: 27467–27473.
19. Broillet MC, Randin O, Chatton J-Y (2001) Photoactivation and calcium sensitivity of the fluorescent NO indicator 4,5-diaminofluorescein (DAF-2): implications for cellular NO imaging. FEBS letters 491: 227–232.
20. Przedborski S, Jackson-Levis V, Yokoyama R, Shibata T, Dawson VL, et al. (1996) Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc Natl Acad Sci USA 93: 4565–4571.
21. Gonchar Y, Burkehalter A (1997) Three distinct families of GABAergic neurons in rat visual cortex. Cerebral Cortex 7: 347–358.
22. Vruwink M, Schmidt HH, Weinberg RJ, Burette A (2001) Substance P and nitric oxide signaling in cerebral cortex: anatomical evidence for reciprocal signaling between two classes of interneurons. J Comp Neurol 441: 298–301.
23. Moreno-Lopez B, Romero-Grimaud C, Noval JA, Murillo-Carretero M, Matarredona ER, et al. (2004) Nitric oxide is a physiological inhibitor of neurogenesis in the adult mouse subventricular zone and olfactory bulb. J Neurosci 24: 85–95.
24. Dehmer T, Ländner J, Haid S, Dichthaus J, Schulz JB (2000) Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo. J Neurochem 74: 2213–2216.
25. Colton GA, Viert MP, Wink DA, Xu Q, Cantillan V, et al. (2006) NO synthase 2 (NOS2) deletion promotes multiple pathologies in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci U S A 103: 12067–72.
34. Demas GE, Eliasson MJ, Dawson TM, Dawson VL, Kriegsfeld LJ, et al. (1997) Inhibition of neuronal nitric oxide synthase increases aggressive behavior in mice. Mol Med 3: 610–6.
35. Demas GE, Kriegsfeld LJ, Blackshaw S, Huang P, Gammie SC, et al. (1999) Elimination of aggressive behavior in male mice lacking endothelial nitric oxide synthase. J Neurosci 19: RC30, 1–5.
36. Chen L, Majde JA, Kriegsfeld LJ (2003) Spontaneous sleep in mice with targeted disruptions of neuronal or inducible nitric oxide synthase genes. Brain Res 973: 214–22.
37. Guimaraes FS, Beijamini V, Moreira FA, Aguiar DC, de Lucca ACB (2005) Role of nitric oxide in brain regions related to defensive reactions. Neurosci Behav Rev 29: 1313–1322.
38. Schafe GE, Bauer EP, Rosis S, Faris CR, Rodrigues SM, et al. (2005) Memory consolidation of Pavlovian fear conditioning requires nitric oxide signaling in the lateral amygdala. Eur J Neurosci 22: 201–11.
39. Guimaraes FS, de Aguiar JC, Del Bel EA, Ballejo G (1994) Anxiolytic effect of nitric oxide synthase inhibitor microinjected into the dorsal central grey. NeuroReport 5: 1929–1932.
40. Pokk P, Vali M (2002) The effects of the nitric oxide synthase inhibitors on the behaviour of small-platform-stressed mice in the plus-maze test. Prog Neuropsychopharmacol Biol Psychiatry 26: 241–247.
41. de Oliveira RW, De Bel EA, Mamede-Rosa ML, Padovan CM, Deakin JF, et al. (2000) Expression of neuronal nitric oxide synthase mRNA in stress-related brain areas after restraint stress. Neurosci Lett 289: 123–126.
42. Moreira FA, Molchanov ML, Guimaraes FS (2003) Flight reactions to nitric oxide in the inferior colliculus of rats depend on NMDA-receptor activation, Pharmacol Biochem Behav. 76: 35–41.
43. Kara P, Friedlander MJ (1999) Arginine analogs modify signal detection by neurons in the visual cortex. J Neurosci 19: 5528–5548.
44. Wang HG, Liu FM, Jin I, Udo H, Kandel ER, et al. (2005) Presynaptic and postsynaptic roles of NO, cGK, and RhoA in long-lasting potentiation and aggregation of synaptic proteins. Neuron 43: 399–403.
45. Chiang LW, Schweizer FE, Tsien RW, Schulman H (1994) Nitric oxide synthase expression in single hippocampal neurons. Brain Res Mol Brain Res. 27: 183–188.
46. Burette A, Zabel U, Weinberg RJ, Schmidt HH, Valochansoff JG (2002) Synaptic localization of nitric oxide synthase and soluble guanylyl cyclase in the hippocampus. J Neurosci 22: 8961–8970.
47. Dinerman JL, Dawson TM, Schell MJ, Snowman A, Snyder SH (1994) Endothelial nitric oxide synthase localized to hippocampal pyramidal cells: implications for synaptic plasticity. Proc Natl Acad Sci USA 91: 4214–4218.
48. Chiang LW, Schweizer FE, Tsien RW, Schulman H (1994) Nitric oxide synthase expression in single hippocampal neurons. Brain Res Mol Brain Res 27: 183–188.
49. Brown LA, Key RJ, Lovick TA (1999) Bio-imaging of nitric oxide-producing neurons in slices of rat brain using 4,5-diaminofluorescein. J Neurosci Methods 92: 7739–7740.
50. Garthwaite G, Bartus K, Malcolm D, Goodwin D, Kolb-Siedecka M, et al. (2006) Signaling from blood vessels to CNS axons through nitric oxide. J Neurosci. 26: 7739–7740.
51. Ikeda H, Murase K (2004) Glial nitric oxide-mediated long-term presynaptic facilitation revealed by optical imaging in rat spinal dorsal horn. J Neurosci 24: 9878–9886.
52. Araque A, Carmignoto G, Haydon PG (2001) Dynamic signaling between astrocytes and neurons. Annu Rev Physiol 63: 795–813.
53. Fellin T, Pascual O, Gobbo S, Pozzan T, Haydon PG, Carmignoto G (2004) Neuronal synchrony mediated by astrocytic glutamate through activation of extrasynaptic NMDA receptors. Neuron 43: 729–741.
54. Newman EA (2003) New roles for astrocytes: regulation of synaptic transmission. TINS 26: 536–542.
55. Gil Z, Amitai Y (1996) Properties of convergent thalamocortical and intracortical synaptic potentials in single neurons of neocortex. J Neurosci 16: 6567–6578.
56. Bardford MM (1976) A rapid and sensitive for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochem 72: 248–254.